STAT
MARCH 5, 2025
It responds poorly to chemotherapy and is usually driven by a mutation that can’t be drugged with traditional approaches. But in a clinical trial presented last year , 14 out of 50 patients with relapsed disease saw their tumors shrink. Median survival is generally cited as less than a year.
STAT
APRIL 14, 2025
An increasing challenge in the treatment of oral cancer is that tumors become resistant to chemotherapy. These studies often do not make a splash in the field and are almost never presented at major meetings, yet they provide guidance as to how best to harness the power of this technology.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmaVoice
JUNE 6, 2025
And the established target of HER2, present in about one in five instances of breast cancer, helped make Enhertu an important entry, Smith said. At ASCO, one of the most talked-about studies was a late-stage trial in which the treatment outperformed chemotherapy as a first-line drug. Smith called it potentially “practice changing.”
Pharmacy Times
JULY 16, 2025
Hematologic malignancy presentations brought long-term evidence of benefit with Bruton tyrosine kinase (BTK) inhibitors and BCL2 combinations in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and promising early-phase results for T-cell engagers (TCEs) in myeloma and lymphoma. months; HR, 0.60; 95% CI, 0.47-0.77);
Pharmacy Times
JUNE 27, 2025
Because of its aggressive nature, MCL is typically treated with combination chemotherapy at diagnosis. Patients often present with peripheral blood, bone marrow, and splenic involvement. For this application, the FDA collaborated with the Australian Therapeutic Goods Administration, Health Canada, and Switzerland’s Swissmedic.
Pharmacy Times
JUNE 9, 2025
A retrospective study presented at the American Society of Health-System Pharmacists 2025 Pharmacy Futures meeting has revealed significant variability in asthma treatment regimens following initial diagnosis, with many patients not receiving care aligned with the Global Initiative for Asthma (GINA) recommendations. REFERENCES 1.
Express Pharma
JANUARY 22, 2025
The company aims to reduce the toxic effects of chemotherapy and chances of cancer relapse improving the quality of lives of patients suffering from cancer. The company also plans to present its data for CDSCO approval, strengthen the team size along with expanding its product marketing and sales at a global level.
Expert insights. Personalized for you.
239 
Let's personalize your content